Evidence map›Paper›PMID 42962023›Full record

ReviewScience advances2026

Augmenting intercellular mitochondrial transfer for tissue repair and rejuvenation.

John Soukar, Kayli Jones, Natalie M Garza, Valeria Duran Salas, Shounak Roy, Vishal M Gohil, Akhilesh K Gaharwar

Abstract readReview
In one paragraph

Review in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

John SoukarInterdisiplinary program in Genetics and Genomics, College of Agriculture and Life Sciences, Texas A&M University, College Station, TX 77843, USA.ORCID 0000-0002-1175-2895
Kayli JonesDepartment of Biomedical Engineering, College of Engineering, Texas A&M University, College Station, TX 77843, USA.ORCID 0009-0002-2951-8666
Natalie M GarzaDepartment of Biochemistry and Biophysics, College of Agriculture and Life Sciences, Texas A&M University, College Station, TX 77843, USA.
Valeria Duran SalasInterdisiplinary program in Genetics and Genomics, College of Agriculture and Life Sciences, Texas A&M University, College Station, TX 77843, USA.ORCID 0009-0003-8595-040X
Shounak RoyDepartment of Biomedical Engineering, College of Engineering, Texas A&M University, College Station, TX 77843, USA.ORCID 0000-0002-9698-6956
Vishal M GohilInterdisiplinary program in Genetics and Genomics, College of Agriculture and Life Sciences, Texas A&M University, College Station, TX 77843, USA.ORCID 0000-0002-9920-2563
Akhilesh K GaharwarInterdisiplinary program in Genetics and Genomics, College of Agriculture and Life Sciences, Texas A&M University, College Station, TX 77843, USA.ORCID 0000-0002-0284-0201

Funding

Mitochondrial Copper BiologyR35GM152102 · NIGMS · TEXAS A&M AGRILIFE RESEARCH · PI Vishal Mahendrasingh Gohil · 2024 to 2026
$1.7M
NIGMS NIH HHS R35 GM152102
6 · The paper itself

Abstract

Cells exhibit innate reparative communication, enabling the exchange of bioactive molecules and, in some cases, entire organelles. Harnessing this endogenous process of intercellular organelle transfer represents an emerging therapeutic paradigm for restoring cellular function in diseases driven by organelle dysfunction. Mitochondrial transfer has gained prominence for its ability to restore bioenergetic capacity, mitigate oxidative stress, and rescue metabolic function in cells with impaired mitochondrial activity. Given that genetic or acquired defects in mitochondrial function are associated with diverse pathologies, including neurodegeneration, cardiovascular diseases, metabolic disorders, skeletal muscle defects, immune dysregulation, and age-associated decline, mitochondrial transfer offers broad therapeutic potential. Mitochondrial transfer seeks to deliver functional mitochondria to injured cells to reestablish metabolic competence. However, insufficient organelle trafficking and limited control over transfer dynamics remain critical barriers to clinical translation. Recent biotechnological developments aimed at enhancing donor-recipient connectivity, increasing mitochondrial availability, and modulating transfer machinery have begun to address some of these key challenges. This review highlights recent advances in mitochondrial transfer bioengineering, emerging therapeutic applications, and key challenges that must be resolved to enable clinical deployment.

Indexed as

MitochondriaRejuvenationWound HealingAnimalsEnergy MetabolismHumansOxidative Stress

Identifiers

PMID42962023
PMCPMC13721982

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.